银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02591 银诺医药-B

未开盘 08-11 16:08:13

7.200

+0.080

+1.12%

最高7.550	最低7.150	成交量300.72万
今开7.150	昨收7.120	日振幅5.62%
总市值32.90亿	流通市值30.26亿	总股本4.57亿
成交额2,205万	换手率0.72%	流通股本4.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药-B","latestPrice":7.2,"timestamp":1786435693007,"preClose":7.12,"halted":0,"volume":3007200,"delay":0,"changeRate":0.011235955056179785,"floatShares":420285370,"shares":457000000,"eps":-0.9188038761818824,"marketStatus":"未开盘","change":0.08,"latestTime":"08-11 16:08:13","open":7.15,"high":7.55,"low":7.15,"amount":22049285,"amplitude":0.05618,"askPrice":7.2,"askSize":108600,"bidPrice":7.195,"bidSize":92600,"shortable":3,"etf":0,"ttmEps":-0.9618364627878692,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786498200000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":7.12,"openAndCloseTimeList":[[1786411800000,1786420800000],[1786424400000,1786435200000]],"volumeRatio":0.6619705908279562,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02591/","defaultTab":"news","newsList":[{"id":"1193985054","title":"银诺医药-B发布2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193985054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193985054?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:02","pubTimestamp":1785920578,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年8月5日发布2026年7月股份变动月报表。报告期为截至2026年7月31日，公司股本结构未现变动，总股本保持稳定。据公告，银诺医药-B由H股及非上市股份两部分组成。本月末两类股份数量均保持不变。报告期末，H股已发行股份数为420,285,370股，非上市股份为36,533,979股，合计已发行股份456,819,349股，库存股数量为0股。上述月报表由联席公司秘书杨东妍签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656837633","title":"银诺医药-B(02591)：两处依苏帕格鲁肽α注射液委托生产场地取得PIC/S GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2656837633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656837633?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:48","pubTimestamp":1785757681,"startTime":"0","endTime":"0","summary":"PIC/S是国际公认的药品检查及认证权威机构，涵盖数十个国家的药品监管机构。GMP合规检查是药品注册及核准的前提条件之一。PIC/S成员国及参与机构自愿相互承认GMP合规检查结果。取得PIC/S GMP证书表明，集团委托生产场地的塬液与制剂制造及品质管理系统符合PIC/S GMP标准。此将进一步扩大集团依苏帕格鲁肽α的商业化产能，并推动该药品于PIC/S成员国完成药品注册及商业化进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B(02591)：两处依苏帕格鲁肽α注射液委托生产场地取得PIC/S GMP证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157662224","title":"银诺医药-B（02591）两处依苏帕格鲁肽α注射液委托生产场地获PIC/S GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1157662224","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157662224?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:46","pubTimestamp":1785757582,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司8月3日公告称，集团位于中国、负责依苏帕格鲁肽α注射液项目的两处委托生产场地已于2026年7月27日通过巴西国家卫生监督管理局依据药品检查合作计划良好生产规范标准开展的合规检查，并获颁相关PIC/S GMP证书。取得上述证书将有助于扩大公司依苏帕格鲁肽α注射液的商业化产能，并推动该产品在PIC/S成员国完成药品注册及商业化进程。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132240036","title":"银诺医药-B：两家Efsubaglutide Alfa注射液委托生产车间获Pic/S GMP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=1132240036","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132240036?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:45","pubTimestamp":1785757512,"startTime":"0","endTime":"0","summary":"银诺医药-B（INNOGEN-B）宣布，其用于Efsubaglutide Alfa注射液的两处合同生产基地，已成功获得Pic/S GMP认证证书。这一里程碑标志着该药品在符合国际生产质量管理规范方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655387175","title":"银诺医药-B(02591)存仓市值总计1.88亿港元 其中股东向花旗银行存入2529.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655387175","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655387175?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:13","pubTimestamp":1785456830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月30日，银诺医药-B(02591)出现仓位异动，存仓市值总计1.88亿港元，占比6.03%。该公司股东将股票存入花旗银行2529.05万股，持股比例增加6.02%。银诺医药截至2025年12月31日止年度业绩显示，集团产生约1.315亿元(人民币，下同)的收入，主要来自于在中国销售依苏帕格鲁肽α。净亏损3.41亿元，同比扩大95.4%；每股基本亏损0.79元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2125154935.USD","LU1366192091.USD","LU2236285917.USD","LU0980610538.SGD","02591","LU0072461881.USD","LU1267930227.SGD","LU0310800965.SGD","LU2125154778.USD","TFNS","LU2360032135.SGD","BK4566","LU1668664300.SGD","BK4207","LU0130102774.USD","LU0098860793.USD","LU0052756011.USD","LU2456880835.USD","LU1244550221.USD","LU2462157665.USD","LU0128525689.USD","LU1201861249.SGD","BK4588","LU1791807156.HKD","LU0162691827.USD","LU1074936037.SGD","LU2417539215.USD","BK4585","LU0320765646.SGD","LU1506573853.SGD","BK1161","LU0477156953.USD","FTXO","LU0203345920.USD","LU1162221912.USD","IE00BSNM7G36.USD","LU0106831901.USD","LU0314106906.USD","LU0170899867.USD","LU1244550577.SGD","LU0203347892.USD","LU0130517989.USD","LU1244550494.USD","LU0648001328.SGD","BK4534","IYF","BK4559","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655176387","title":"银诺医药-B(02591.HK)存仓市值总计1.88亿港元 其中股东向花旗银行存入2529.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655176387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655176387?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:13","pubTimestamp":1785456830,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655834385","title":"银诺医药-B(02591.HK)存仓市值总计6.53亿港元 其中股东向中信证券经纪香港存入8424.74万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655834385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655834385?lang=zh_cn&edition=full","pubTime":"2026-07-29 08:34","pubTimestamp":1785285257,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1564","02591","LU1794554557.SGD","LU1720050803.USD","BK1161","06030","BK1521","BK1147","BK1516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163632886","title":"银诺医药-B完成依苏帕格鲁肽α治疗青少年肥胖症Ib期首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1163632886","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163632886?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:31","pubTimestamp":1785241900,"startTime":"0","endTime":"0","summary":"2026年7月28日，银诺医药-B（02591）公告称，其依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验已完成首例受试者入组并给药。公司表示，在观察期内未发现任何安全性问题或不良反应。该项目按公司于2026年6月22日公告的时间表，于2026年7月启动。  \n   \n银诺医药-B指出，将继续依据适用监管规定披露该临床项目的重大进展，并提醒投资者公司无法保证最终能够成功开发或商业化该产品。  \n   \n公司董事会主席WANG QINGHUA博士代表董事会于2026年7月28日在上海签署本次自愿性公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654004232","title":"银诺医药-B(02591.HK)完成依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验首例受试者入组及给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654004232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654004232?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:27","pubTimestamp":1785241628,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650156844","title":"银诺医药（02591.HK）公开回应专利侵权诉讼风波，股价由跌返涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2650156844","media":"广州日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650156844?lang=zh_cn&edition=full","pubTime":"2026-07-11 15:54","pubTimestamp":1783756453,"startTime":"0","endTime":"0","summary":"针对苏州嘉树生物认为银诺医药侵犯其公司的“实用新型专利侵权”一案，银诺医药在官方公众号发布《五个事实，还原银诺医药专利诉讼事实真相》一文，正面回应诉讼风波。受此消息影响，叠加7月10日港股市场生物技术股再度强势大涨的大势，银诺医药-B（02591.HK）10日走势由跌返涨，盘中拉升一度涨超7%，最终报7.990港元收市，涨幅0.38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607113802508245.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607113802508245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181179561","title":"银诺医药-B 6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1181179561","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181179561?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:44","pubTimestamp":1783327463,"startTime":"0","endTime":"0","summary":"广州银诺医药集团股份有限公司于2026年7月6日发布截至2026年6月30日的证券变动月报表。报告显示，企业本期注册股本总额为人民币456,819,349元，其中约420,285,370股为上市的H股，36,533,979股为非上市股份。面值均为人民币1元，报告期内无增减变化，股本保持稳定。公司披露，截至6月末，上市H股和非上市股份均无新增发行、无购回或注销，也未持有任何库藏股份。公司确认截至6月末所发行H股继续满足香港联交所上市规则的相关公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001934","title":"港股异动 | 银诺医药-B(02591)现涨超17% 依苏帕格鲁肽α青少年减重IND获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001934","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645001934?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:53","pubTimestamp":1782179598,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B现涨超17%，截至发稿，涨14.03%，报8.94港元，成交额4571.24万港元。消息面上，银诺医药宣布，其自主研发的长效GLP-1受体激动剂药物依苏帕格鲁肽α注射液获得国家药品监督管理局批准，在12至17岁肥胖或超重且合并相关并发症的青少年中开展减重Ib期临床试验。公开资料显示，依苏帕格鲁肽α作为长效GLP-1受体激动剂，已在成人肥胖人群中显示出良好的减重效果及可接受的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","IND","02591","BK1161","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645430770","title":"银诺医药-B(02591)：收到国家药监局批准可开展依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2645430770","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645430770?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:44","pubTimestamp":1782103443,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2026年6月17日，集团已收到中国国家药品监督管理局的批准，可开展集团依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验。公司预期该临床试验将于2026年7月开始，并计划就该临床试验招募约36位参与者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B(02591)：收到国家药监局批准可开展依苏帕格鲁肽α用于治疗青少年肥胖症的Ib期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110840346","title":"银诺医药-B获中国批准启动Efsubaglutide Alfa针对青少年肥胖症的Ib期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1110840346","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110840346?lang=zh_cn&edition=full","pubTime":"2026-06-22 12:09","pubTimestamp":1782101359,"startTime":"0","endTime":"0","summary":"6月17日，广州银诺医药集团有限公司宣布，其研发的Efsubaglutide Alfa已获得中国监管部门的批准，将启动针对青少年肥胖症的Ib期临床试验。\n这一进展标志着该药物在拓展适应症方面取得了重要突破。Efsubaglutide Alfa是一种新型的胰高血糖素样肽-1（GLP-1）受体激动剂，此前已在成人肥胖症领域展现出潜力。此次获批进入青少年群体研究，有望为这一日益严峻的公共卫生问题提供新的治疗选择。\n临床试验的启动将遵循严格的研究方案，以评估药物在该特定年龄组中的安全性、耐受性及初步疗效。公司表示，将积极推进后续研究工作，并期待为全球肥胖症治疗领域贡献更多数据与方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114079905","title":"银诺医药-B授予董事会股份购回授权，规模达已发行H股一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1114079905","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114079905?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:29","pubTimestamp":1780658990,"startTime":"0","endTime":"0","summary":"银诺医药-B发布公告称，其董事会已建议在2026年6月29日召开的股东周年大会上审议并授予股份购回授权，授权范围最高可回购不超过已发行H股总数10%的股份，即最多约420,285,370股的10%，相当于约42,028,537股H股。根据相关安排，本次购回议案将于股东周年大会上表决，股东名册的记录日为2026年6月29日，期间公司将暂停H股股份过户登记，股东可在规定期限内提交有效登记及表决委托。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"银诺医药-B授予董事会股份购回授权，规模达已发行H股一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641191607","title":"港股异动 | 银诺医药-B(02591)盘中涨超9% 原研依苏帕格鲁肽α亮相第17届CADA年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641191607","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641191607?lang=zh_cn&edition=full","pubTime":"2026-06-05 11:08","pubTimestamp":1780628920,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B盘中涨超9%，截至发稿，涨3.21%，报10.28港元，成交额3487.24万港元。值得注意的是，今年4月，银诺医药依苏帕格鲁肽α正式纳入“齐鲁保”互联网门诊特定药品清单，用于成人2型糖尿病患者治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK4588","BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150072856","title":"银诺医药-B 5月无新增发行或回购，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1150072856","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150072856?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:13","pubTimestamp":1780477988,"startTime":"0","endTime":"0","summary":"银诺医药-B于2026年6月3日发布截至2026年5月31日的股份变动月报表。根据公告，报告期内公司在香港联合交易所上市流通的H股数量为420,285,370股，非上市股份数量为36,533,979股，两类股份合计数量为456,819,349股，均与上期末保持一致。公告显示，报告期内公司注册股本、已发行股本及库藏股份数目均未发生变动，未进行任何新增发行、购回或注销股份的活动；公司亦未涉及股份期权或股权激励计划的授予、行使或失效事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978683","title":"港股异动 | 银诺医药-B(02591)涨超6% 将于ADA 2026大会报告依苏帕格鲁肽α中国IIb期临床研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978683","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640978683?lang=zh_cn&edition=full","pubTime":"2026-06-03 11:01","pubTimestamp":1780455694,"startTime":"0","endTime":"0","summary":"消息面上，近日，据银诺医药官微消息，公司宣布，将在2026年美国糖尿病协会科学会议上，报告依苏帕格鲁肽α的中国IIb期临床研究数据。本次大会将于2026年6月5日至8日在美国新奥尔良举行。据介绍，银诺医药自主研发的依苏帕格鲁肽α在中国超重/肥胖患者中开展的2b期ENLIGHT研究顶线数据达到主要研究终点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127935748","title":"异动解读｜银诺医药-B盘中上涨10.68%，拟采纳股份奖励计划叠加商业化加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1127935748","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127935748?lang=zh_cn&edition=full","pubTime":"2026-06-03 10:38","pubTimestamp":1780454283,"startTime":"0","endTime":"0","summary":"6月3日，银诺医药-B盘中上涨10.68%，报11.1港元/股，成交额2310.6万港元，逆势大幅跑赢生物科技板块。消息面上，公司于6月1日公告拟采纳股份奖励计划，旨在完善激励机制、吸引及留任核心人才，计划将于6月29日股东周年大会上审议批准。此外，公司正探索伴侣动物糖尿病及肥胖等新应用领域，相关新兽药临床试验申请已获受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895041","title":"银诺医药-B(02591)拟采纳股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895041","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640895041?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:36","pubTimestamp":1780324603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发并公告，董事会已建议采纳股份奖励计划。根据组织章程细则的规定，将于股东周年大会上提呈一项特别决议案，以审议及批准建议采纳计划。计划须待股东于2026年6月29日举行的股东周年大会上批准后方告生效。计划的目的旨在完善本公司的激励机制，透过授予奖励以吸引、激励及留任本公司的选定雇员、关联实体的员工及本公司服务提供者，从而进一步提升参与者的积极性及创造力。计划项下的参与者应受到激励，以更好及稳定的长期方式为本公司服务、创造价值及作出贡献，促进本公司业绩的持续增长，并在提升本公司价值的同时为参与者带来增值利益，从而实现参与者与本公司的共同发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","301122","02591","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innogenpharm.com","stockEarnings":[{"period":"1week","weight":-0.0062},{"period":"1month","weight":-0.0989},{"period":"3month","weight":-0.5024},{"period":"6month","weight":-0.7366},{"period":"1year","weight":-0.6146},{"period":"ytd","weight":-0.765}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州银诺医药集团股份有限公司是一家主要从事医药产品的研发及商业化的中国投资控股公司。该公司主要从事商业化原研人源长效胰高血糖素样肽-1（GLP-1）受体激动剂。该公司致力于开发糖尿病和其他代谢性疾病的疗法。该公司的主要产品依苏帕格鲁肽α（商品名：怡诺轻）用于治疗2型糖尿病（T2D）。该公司的主要候选药物管线产品包括YN014、YN401、YN209、YN203和YN202。该公司主要在国内市场经营其业务。","exchange":"SEHK","name":"银诺医药-B","nameEN":"INNOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"银诺医药-B,02591,银诺医药-B股票,银诺医药-B股票老虎,银诺医药-B股票老虎国际,银诺医药-B行情,银诺医药-B股票行情,银诺医药-B股价,银诺医药-B股市,银诺医药-B股票价格,银诺医药-B股票交易,银诺医药-B股票购买,银诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"银诺医药-B(02591)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供银诺医药-B(02591)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}